Among several new options for male contraceptives mentioned in this article is Gendarussa, a product that prevents sperm from fertilizing an egg. FHI 360 developed protocols for the next phase of clinical trial for this product. Paul Feldblum, FHI 360 Senior Epidemiologist, says Gendarussa received clearance from the Indonesian equivalent of the U.S. Food and Drug Administration to proceed with Phase 2 trials.
